drugset / Trial / NCT01573780

Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

NCT01573780

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the dose of smac mimetic TL32711 that is safe and tolerated when given with gemcitabine hydrochloride to patients with advanced cancer

Timeline

Start
2012-04
Primary completion
2013-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Birinapant Small molecule Intravenous
Subject Gemcitabine Small molecule Intravenous